Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i>-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model

Takashi Murakami, Arun S. Singh, Tasuku Kiyuna, +19

Oncotarget

PathologyEffective Molecular TargetingCancer BiologyTumor BiologyPdox Model +18

High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model

Tasuku Kiyuna, Takashi Murakami, Yasunori Tome, +11

Oncotarget

Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model

Kei Kawaguchi, Kentaro Igarashi, Takashi Murakami, +12

Oncotarget

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han, +14

Cancer Letters

Oral Recombinant MethioninaseOncologyPancreatic CancerMedicineGemcitabine Resistance +4

Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model

Takashi Murakami, Shukuan Li, Qinghong Han, +19

Oncotarget

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model

Kei Kawaguchi, Takashi Murakami, Bartosz Chmielowski, +9

Oncotarget

Mek-targeting Drug TrametinibImmunotherapeuticsDermatologyArrest Tumor GrowthTumor Biology +17

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model

Kei Kawaguchi, Kentaro Igarashi, Shukuan Li, +13

Oncotarget

Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, +20

Cell Cycle

Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma

Kentaro Igarashi, Kei Kawaguchi, Shukuan Li, +20

Cancer Letters

Tumor BiologyCancer Cell BiologyFirst-line Dox ResistanceUndifferentiated Spindle-cell SarcomaRadiation Oncology +4

Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

Kei Kawaguchi, Qinghong Han, Shukuan Li, +15

Cell Cycle

Chemoprevention StrategyBraf-v600e Mutant MelanomaTumor BiologyOncologyElevated Methionine +17